Actual problems in occupational lung diseases

1. Artiomova L.V., Kuzmina L.P., Sorkina N.S., et al. Topical aspects of contemporary forms of occupational bronchial asthma / Occupation Medicine and Industrial ecology=Medicina truda i promyshlennaja jekologija 2014. (7) 19-24. . [In Russian]
2. Russian Rheumatology Association [Electronic resource]. National Federal guidelines for the rheumatic diseases. URL http://www.rheumatolog.ru/experts/klinicheskie-rekomendacii. . [In Russian]
3. Pilishenko V.A., Glushkova N.Ju., Kurkin D.P. The state of occupational diseases in the Russian Federation in 2011. Information Collection analytical materials. M.: Federal'nyj centr gigieny i jepidemiologii Rospotrebnadzora. 2012. – 48 P. . [In Russian]
4. Order of the Ministry of Health and Social Development of 27.04.2012№417n "On approval of the list of occupational diseases", registered in the Ministry of Justice 15.05.2012г, №24168. [In Russian]
5. ILO Recommendation number 194. On the list of occupational diseases, notification of occupational accidents and occupational diseases and their registration. [Electronic resource]. URL: http://www.conventions.ru/view_base.php?id=625 . [In Russian]
6. Smirnova E.L., Poteryaeva E.L., Nikiforova N.G etc. Prediction of the cause of pneumoconiosis in the post-exposure period based on an assessment of individual risk factors // Occupation and health: Proceedings of the IX All-Russian Congress and IV All-Russian Congress of occupational medicine specialists. – М., 2010. – P.. 474–476. . [In Russian]
7. Fomina V.S., Kuz'mina L. P. Matrix metalloproteinase (pro-MMP-1, MMP-2,8) and their inhibitors (TIMP-1) evaluation in patients with occupational lung disease / Occupation Medicine and Industrial ecology=Meditsina truda i promyshlennaya ekologiya. 2010 (7) 29-33. [In Russian]
8. A.G. Chuchalin, L.A. Shpagina, O.S. Vasilyeva etc. Occupational chronic obstructive pulmonary disease / Occupational lung diseases. National guidelines. M.: GEOTAR, 2015. 293 – 338. [In Russian]
9. L.A.Shpagina, M.I.Voevoda, O.S.Kotova etc.. Occupational chronic obstructive pulmonary disease from the point of molecular genetic research// Bulletin of physiology and pathology of Respiration=Byulleten' fiziologii i patologii dykhaniya. 2013. (49) 8–15. . [In Russian]
10. Agusti A., Bel E., Thomas M. et al. Treatable traits: toward precision medicine of chronic airway diseases // Eur Respir J. 2016 47 410-419.
11. Annesi-Maesano I., Lundbäck B., Viegi G. Respiratory Epidemiology. ERS. 2014. – 273 P.
12. Beier J., Kirsten A.M., Mróz R. et al. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled Phase IIIb study // COPD. 2013. 10 511-522.
13. Brüske I., Thiering E., Heinrich J. et al. Biopersistent granular dust and chronic obstructive pulmonary disease: a systematic review and meta-analysis // PLoS One. 2013. 8 e80977.
14. Calverley P.M., Rabe K.F., Goehring U.M. et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials// Lancet 2009. 374 685-694.
15. Centers for Disease Control and Prevention (CDC). Pneumoconiosis and advanced occupational lung disease among surface coal miners--16 states, 2010-2011 // MMWR Morb Mortal Wkly Rep. 2012. 61 431–434.
16. Chapman K.R.Beeh K.M., Beier J et al. A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study // BMC Pulm Med. 2014. 14 4.
17. Eisner M.D., Anthonisen N., Coultas D. et al. An official American Thoracic Society public policy statement: Novel risk factors and the global burden of chronic obstructive pulmonary disease // Am J Respir Crit Care Med. 2010. 182 693-718
18. Global Initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (revised 2016). Available from URL: http://www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management.html. 2016.
19. McGrath K.W., Icitovic N., Boushey H.A. et al., A large subgroup of mild-to-moderate asthma is persistently noneosinophilic // Am J Respir Crit Care Med. 2012. 185 612-619.
20. de Jong K., Boezen H.M., Kromhout H. et al. Pesticides and other occupational exposures are associated with airway obstruction: the LifeLines cohort study // Occup Environ Med. 2014. 71 88-96.
21. Kornmann O, Dahl R, Centanni S, et al. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison // Eur Respir J 2011. 37 273-279.
22. Kukkonen M.K., Tiili E., Vehmas T. et al. Association of genes of protease-antiprotease balance pathway to lung function and emphysema subtypes // BMC Pulm Med. 2013. 13. 36.
23. Lavaud F., Bonniaud P., Dalphin J.C. et al. Usefulness of omalizumab in ten patients with severe occupational asthma // Allergy. 2013. 68. 813-5.
24. Mahler D.A., Decramer M., D'Urzo A. et al., Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study // Eur Respir J. 2014. 43 1599-1609.
25. Malo J.L., Tarlo S.M., Sastre J. et al. An official American Thoracic Society Workshop Report: presentations and discussion of the fifth Jack Pepys Workshop on Asthma in the Workplace. Comparisons between asthma in the workplace and non-work-related asthma. // Ann Am Thorac Soc. 2015 12 S99-S110
26. Mariotti F., Ciurlia G., Spaccapelo L. et al., A Two-Period Open-Label, Single-Dose Crossover Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Between Cimetidine and Inhaled Extrafine CHF 599 // Eur J Drug Metab Pharmacokinet. 2016 Available from URL: http://link.springer.com/article/10.1007%2Fs13318-016-0345-2
27. Martinez F.J., Boscia J., Feldman G. et al., Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: a randomised trial // Respir Med. 2013. 107 550-559.
28. Miravitlles M., Soler-Cataluna J.J., Calle M., Soriano J.B. Treatment of COPD by clinical phenotypes: putting old evidence into clinical practice // Eur Respir J 2013. 41 1252-1256
29. Normansell R., Walker S., Milan S.J. et al. Omalizumab for asthma in adults and children // Cochrane Database Syst Rev. 2014. (1) CD003559.
30. Paulin L.M., Diette G.B., Blanc P.D. et al. Occupational exposures are associated with worse morbidity in patients with chronic obstructive pulmonary disease // Am J Respir Crit Care Med. 2015. 191 557-565.
31. Pavord I.D., Lettis S., Locantore N. et al. Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD // Thorax. 2016. 71 118-125.
32. Pavord I.D., Korn S., Howarth P. et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial // Lancet. 2012. 380. 651-659.
33. Postma D.S., Roche N., Colice G. et al., Comparing the effectiveness of small-particle versus large-particle inhaled corticosteroid in COPD // Int J Chron Obstruct Pulmon Dis. 2014. 9 1163-1186.
34. Rodríguez E., Ferrer J., Zock J.P. et al., Lifetime occupational exposure to dusts, gases and fumes is associated with bronchitis symptoms and higher diffusion capacity in COPD patients // PLoS One. 2014. 9 e88426.
35. Singh D., Jones P.W., Bateman E.D. et al., Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study // BMC Pulm Med. 2014. 14 178
36. Singh D., Kolsum U., Brightling C.E. et al. Eosinophilic inflammation in COPD: prevalence and clinical characteristics // Eur Respir J. 2014.44 1697-1700.
37. Singh D., Gaga M., Schmidt O. et al., Effects of tiotropium + olodaterol versus tiotropium or placebo by COPD disease severity and previous treatment history in the OTEMTO® studies // Respir Res. 2016. 17. 73.
38. Suissa S., Dell'Aniello S., Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality // Thorax. 2012. 67 957-963.
39. Taniguchi H., Ebina M., Kondoh Y. et al. Pirfenidone in idiopathic pulmonary fibrosis // Eur Respir J. 2010. 4 821-829.

Shpagina L.A. – doctor of medical sciences, professor, head of the department of internal medicine and medical rehabilitation, e-mail: mkb-2@yandex.ru